




The Sad Reality

Chronic Kidney Disease (CKD) is a progressive condition where kidneys lose the ability to remove toxins from the blood, affecting ~850 million people globally and is the 8th leading cause of death in the US. There is a gap in treatment and there are no patient friendly therapies in the market. Despite over \$50B in annual US spend, dialysis fails to remove Protein-Bound Uremic Toxins and phosphate, causing cardiovascular damage and high mortality.

Bubble Tea: A Delicious Alternative



TheraT is a non invasive, drinkable therapy that captures uremic toxins directly in the gut before they reach the bloodstream. It uses pH responsive hydrogel beads that safely carry microbes and binders, enabling targeted toxin removal while passing intact through the digestive system. By reducing toxin burden without needles or blood access, TheraT can be used anywhere, and offers a scalable patient-friendly alternative to current treatments in the market.

Market Opportunity

TheraT will initially enter the \$2B phosphate binder market, and then expand further into therapeutic kidney care by targeting the removal of urea and PBUT to disrupt the dialysis market, which is valued at \$100B.

Financials

	Year 1-5	Year 6	Year 7	Year 8
Revenue	0	\$18.75M	\$44M	\$116M
Expenses	\$50M	\$40M	\$60M	\$79M
Net	(\$50M)	(\$21.25M)	(\$16M)	\$37M

Go-To-Market

Phase 1 (Year 1-5)

Market Entry and Clinical validation

- Target the phosphate binder market as our beach head.
- Build relationships with nephrologists.
- Start clinical trials to get validation.

Phase 2 (Year 5+)

FDA Regulatory Approval and Commercialization

- Secure FDA approval for phosphate regulation.
- Secure insurance reimbursement
- Scale manufacturing and distribution through strategic partners.

Phase 3 (Year 6+)

Portfolio expansion and Company growth

- Expand technology applications to target other kidney-associated toxins.
- Broaden the market potential.